The study by the Center Valley, Pa.-based implant developer compared Aesculap’s ActivL Artificial Disc with Centinel Spine’s ProDisc-L, reporting outcomes seven years postsurgery — “the longest follow-up of patients from a lumbar arthroplasty [investigational device exemption] trial,” according to Kris Radcliff, MD.
According to the trial, the benefits of both the ActivL and ProDisc-L remained seven years postprocedure, “with significant improvements from baseline observed in pain, function, and opioid use.” However, patients with the ActivL disc showed better range of motion than those with the ProDisc-L, and 57 percent of ProDisc-L patients reported “serious adverse events,” compared with 38 percent of ActivL patients.
Another study from this year published in the Journal of Orthopaedic Surgery and Research on the ActivL found that, three years postsurgery, patients had overall better sagittal alignment and experienced less pain.
Read more about Aesculap’s study here.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.